or Try an Advanced Search...

    Technical Analysis for ATXS - Astria Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 9.27 -2.32% -0.22
    ATXS closed down 2.32 percent on Wednesday, May 15, 2024, on 58 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ATXS trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Multiple of Ten Bearish Other 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    20 DMA Resistance Bearish -2.32%
    Outside Day Range Expansion -2.32%
    Older End-of-Day Signals for ATXS ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 15 hours ago
    Outside Day about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    20 DMA Resistance about 16 hours ago
    20 DMA Support about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ATXS Chart by TradingView
    Basic chart:

    Profile

    Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Immunology Monoclonal Antibody Antibody Angioedema Hereditary Angioedema Kallikrein Complement Deficiency

    Is ATXS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 11 We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
    May 10 Astria TherapeuticS GAAP EPS of -$0.38 misses by $0.02
    May 9 Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    May 8 Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
    Apr 9 Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
    Apr 3 Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
    Mar 25 Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
    Mar 23 Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
    Mar 4 Astria TherapeuticS GAAP EPS of -$2.42 misses by $0.19
    Mar 4 Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    See more ATXS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.9
    52 Week Low 4.26
    Average Volume 1,093,862
    200-Day Moving Average 9.04
    50-Day Moving Average 11.88
    20-Day Moving Average 9.57
    10-Day Moving Average 9.66
    Average True Range 0.65
    RSI (14) 37.50
    ADX 20.18
    +DI 14.64
    -DI 17.79
    Chandelier Exit (Long, 3 ATRs) 9.38
    Chandelier Exit (Short, 3 ATRs) 10.72
    Upper Bollinger Bands 10.33
    Lower Bollinger Band 8.80
    Percent B (%b) 0.31
    BandWidth 16.01
    MACD Line -0.54
    MACD Signal Line -0.68
    MACD Histogram 0.1385
    Fundamentals Value
    Market Cap 506.75 Million
    Num Shares 54.7 Million
    EPS -2.12
    Price-to-Earnings (P/E) Ratio -4.37
    Price-to-Sales 0.00
    Price-to-Book 9.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.46
    Resistance 3 (R3) 10.58 10.31 10.26
    Resistance 2 (R2) 10.31 10.01 10.25 10.19
    Resistance 1 (R1) 9.79 9.82 9.66 9.67 10.13
    Pivot Point 9.52 9.52 9.45 9.46 9.52
    Support 1 (S1) 9.00 9.22 8.87 8.88 8.41
    Support 2 (S2) 8.73 9.03 8.67 8.35
    Support 3 (S3) 8.21 8.73 8.28
    Support 4 (S4) 8.09